We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Horizon (HZNP) holds preliminary discussions with Amgen, Sanofi and Janssen, a subsidiary of J&J, seeking an offer for its acquisition by any one of the pharma giants. Shares rise.
Gilead (GILD) and RCUS release encouraging data from the fourth interim analysis of the phase II ARC-2 study in patients with first-line metastatic non-small cell lung cancer (NSCLC).
AbbVie (ABBV) boasts several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.
Novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.
Palisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal (GI) surgery.
Top-line data from a late-stage study shows that Merck's (MRK) Keytruda combined with chemotherapy improved overall survival in patients with advanced gastric cancer.
GSK, at the request of the FDA, is set to withdraw the U.S. marketing authorization for Blenrep. The FDA's request comes after the failure of a phase III confirmatory study, DREAMM-3.
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), PepsiCo, Inc. (PEP) and The Walt Disney Company (DIS).
bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, will likely drive the top line.
Biotech giant Bristol Myers (BMY) outperforms the industry and the S&P 500 Index as Eliquis and Opdivo maintain momentum despite generic competition for Revlimid.
Jazz Pharma (JAZZ) gets FDA approval for an MWF intramuscular (IM) dosing schedule for Rylaze to treat acute lymphoblastic leukemia or lymphoblastic lymphoma with hypersensitivity to asparaginase.
pharmaceuticals: Archive
Horizon (HZNP) Up on Initial Talks of Buyout by Pharma Giants
by Zacks Equity Research
Horizon (HZNP) holds preliminary discussions with Amgen, Sanofi and Janssen, a subsidiary of J&J, seeking an offer for its acquisition by any one of the pharma giants. Shares rise.
SNYNegative Net Change JNJNegative Net Change AMGNNegative Net Change HZNPPositive Net Change
biotechs pharmaceuticals
AstraZeneca (AZN) Boosts Cell Therapies With Neogene Deal
by Zacks Equity Research
The acquisition of Neogene is set to give AstraZeneca (AZN) access to the latter's next-generation T-cell receptor therapies.
AZNPositive Net Change MRKNegative Net Change GILDPositive Net Change VRTXNegative Net Change
pharmaceuticals
CinCor (CINC) Tanks Due to Dismal Data on Hypertension Drug
by Zacks Equity Research
CinCor (CINC) plummets as its phase II study, HALO, evaluating its lead candidate baxdrostat for hypertension, fails to meet its primary endpoint.
BIIBPositive Net Change GILDPositive Net Change SLDBNegative Net Change CINCNegative Net Change
biotechnology pharmaceuticals
Gilead (GILD), RCUS Announce Positive Data From NSCLC Study
by Zacks Equity Research
Gilead (GILD) and RCUS release encouraging data from the fourth interim analysis of the phase II ARC-2 study in patients with first-line metastatic non-small cell lung cancer (NSCLC).
BIIBPositive Net Change GILDPositive Net Change SLDBNegative Net Change RCUSPositive Net Change
biotechnology biotechs pharmaceuticals
Spectrum's (SPPI) NDA for NSCLC Candidate Gets CRL From FDA
by Zacks Equity Research
Spectrum (SPPI) gets a CRL from the FDA for poziotinib as the agency requires additional data. The company de-prioritized the poziotinib program.
BIIBPositive Net Change GILDPositive Net Change SPPINegative Net Change SLDBNegative Net Change
pharmaceuticals
Here's What's Driving AbbVie's (ABBV) Outperformance This Year
by Zacks Equity Research
AbbVie (ABBV) boasts several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.
RHHBYNegative Net Change JNJNegative Net Change ABBVNegative Net Change GMABPositive Net Change
pharmaceuticals
Incyte (INCY) Outperforms YTD: Will the Momentum Continue?
by Zacks Equity Research
Incyte (INCY) outperforms the biotech industry in the year so far and the momentum should continue in 2023 as well.
NVSPositive Net Change LLYNegative Net Change INCYPositive Net Change SNDXPositive Net Change
biotechnology biotechs pharmaceuticals
Regeneron (REGN) Outperforms YTD: What's in Store for 2023?
by Zacks Equity Research
Regeneron (REGN) has had a good run in 2022 so far and the momentum should continue in 2023 as well.
REGNNegative Net Change SNYNegative Net Change BAYRYNegative Net Change
biotechnology pharmaceuticals
Pharma Stock Roundup: MRK to Buy IMGO, ABBV's Skyrizi Gets EU Nod for New Indication
by Kinjel Shah
Merck (MRK) offers to buy Imago Biosciences (IMGO). The European Commission approves AbbVie's (ABBV) immunology medicine, Skyrizi for Crohn's disease.
GSKNegative Net Change MRKNegative Net Change ABBVNegative Net Change IMGONegative Net Change
pharmaceuticals
Novartis (NVS) Set to Advance Malaria Drug Into Phase III
by Zacks Equity Research
Novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.
NVSPositive Net Change BIIBPositive Net Change RHHBYNegative Net Change MRKNegative Net Change
pharmaceuticals
AbbVie's (ABBV) Skyrizi Gets EU Nod for Crohn's Disease
by Zacks Equity Research
AbbVie's (ABBV) Skyrizi becomes the first specific IL-23 inhibitor to get approval for Crohn's disease in the European Union.
MRKNegative Net Change GILDPositive Net Change VRTXNegative Net Change ABBVNegative Net Change
pharmaceuticals
Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track Designation
by Zacks Equity Research
Palisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal (GI) surgery.
AVEONegative Net Change ETONPositive Net Change IMCRPositive Net Change PALINegative Net Change
medical pharmaceuticals
Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update
by Zacks Equity Research
Updates from CTMX and APLS are the key highlights from the biotech sector during the past week.
REGNNegative Net Change CTMXPositive Net Change APLSNegative Net Change INMPositive Net Change
biotechnology biotechs pharmaceuticals
Merck (MRK) Keytruda Advanced Gastric Cancer Study Meets Goal
by Zacks Equity Research
Top-line data from a late-stage study shows that Merck's (MRK) Keytruda combined with chemotherapy improved overall survival in patients with advanced gastric cancer.
BMYNegative Net Change MRKNegative Net Change VRTXNegative Net Change ANGNNegative Net Change
medical pharmaceuticals
GSK to Withdraw Blenrep From U.S. Market on FDA Request
by Zacks Equity Research
GSK, at the request of the FDA, is set to withdraw the U.S. marketing authorization for Blenrep. The FDA's request comes after the failure of a phase III confirmatory study, DREAMM-3.
GSKNegative Net Change MRKNegative Net Change GILDPositive Net Change VRTXNegative Net Change
pharmaceuticals
The Zacks Analyst Blog Highlights AbbVie PepsiCo, The Walt Disney, Caterpillar and PBF Energy
by Zacks Equity Research
AbbVie, PepsiCo, The Walt Disney, Caterpillar and PBF Energy are part of The Zacks top Analyst Blog.
CATNegative Net Change PEPNegative Net Change DISNegative Net Change ABBVNegative Net Change PBFNegative Net Change
consumer-discretionary consumer-staples industrial-products oil-energy pharmaceuticals
The Zacks Analyst Blog Highlights Archer-Daniels-Midland, McKesson, Marathon Petroleum, Exxon Mobil and Merck & Co
by Zacks Equity Research
Archer-Daniels-Midland, McKesson, Marathon Petroleum, Exxon Mobil and Merck & Co are part of the Zacks top Analyst Blog.
XOMNegative Net Change MRKNegative Net Change ADMNegative Net Change MCKNegative Net Change MPCNegative Net Change
consumer-staples medical oil-energy pharmaceuticals
Top Stock Reports for AbbVie, PepsiCo & Walt Disney
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), PepsiCo, Inc. (PEP) and The Walt Disney Company (DIS).
CATNegative Net Change BKNegative Net Change AFLNegative Net Change PEPNegative Net Change DISNegative Net Change ABBVNegative Net Change
consumer-discretionary consumer-staples pharmaceuticals
bluebird bio (BLUE) Rides High on Its Gene Therapy Approvals
by Zacks Equity Research
bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, will likely drive the top line.
AVEONegative Net Change BLUENegative Net Change ETONPositive Net Change IMCRPositive Net Change
medical pharmaceuticals
Buy These 5 Corporate Giants Flying High in Disappointing 2022
by Nalak Das
We have narrowed our search to five U.S. corporate behemoths that have popped year to date. These are: ADM, MPC, XOM, MRK and MCK.
XOMNegative Net Change MRKNegative Net Change ADMNegative Net Change MCKNegative Net Change MPCNegative Net Change
agriculture medical oil-energy pharmaceuticals
AbbVie (ABBV) BLA for Epcoritamab Gets FDA Priority Tag
by Zacks Equity Research
The FDA grants priority review status to AbbVie's (ABBV) BLA for epcoritamab for the relapsed/refractory large B-cell lymphoma (LBCL), a form of NHL.
MRKNegative Net Change VRTXNegative Net Change ABBVNegative Net Change GMABPositive Net Change
pharmaceuticals
Bristol Myers (BMY) Gains 24.2% YTD: What's in Store for 2023?
by Zacks Equity Research
Biotech giant Bristol Myers (BMY) outperforms the industry and the S&P 500 Index as Eliquis and Opdivo maintain momentum despite generic competition for Revlimid.
BMYNegative Net Change LLYNegative Net Change GILDPositive Net Change
biotechnology pharmaceuticals
Jazz Pharma's (JAZZ) Gets FDA Nod for Rylaze's New Dosing Option
by Zacks Equity Research
Jazz Pharma (JAZZ) gets FDA approval for an MWF intramuscular (IM) dosing schedule for Rylaze to treat acute lymphoblastic leukemia or lymphoblastic lymphoma with hypersensitivity to asparaginase.
JAZZPositive Net Change ESPRPositive Net Change ZYMENegative Net Change ASRTNo Net Change
medical pharmaceuticals
Pfizer (PFE), BioNTech Provide New Data on BA.4/BA.5 Boosters
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) Omicron BA.4/BA.5-adapted bivalent vaccines show improved immune response against newer Omicron sublineages.
PFENegative Net Change MRKNegative Net Change MRNANegative Net Change BNTXPositive Net Change
pharmaceuticals
Gilead (GILD) Outperforms YTD: Will It Retain the Momentum?
by Zacks Equity Research
Biotech giant Gilead (GILD) outperforms the industry and the S&P 500 Index as its core business maintains momentum despite volatility.
GSKNegative Net Change GILDPositive Net Change PBYINegative Net Change SNDXPositive Net Change
biotechnology pharmaceuticals